COVID-19.рф: ИНФОРМАЦИЯ ПРОТИВ ПАНДЕМИИ

Поиск по репозиторию

Статья

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

R. Acevedo, X. Bai, R. Borrow, D. Caugant, J. Carlos, M. Ceyhan, H. Christensen, Y. Climent, W. De, E. Dinleyici, G. Echaniz-Aviles, A. Hakawi, H. Kamiya, A. Karachaliou, J. Lucidarme, S. Meiring, K. Mironov, M. Sáfadi, Z. Shao, V. Smith, R. Steffen, B. Stenmark, M. Taha, C. Trotter, J. Vázquez, B. Zhu,
2021
https://doi.org/10.1080/14760584.2019.1557520

Introduction: The 2018 Global Meningococcal Initiative (GMI) meeting focused on evolving invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies worldwide, with emphasis on emerging antibiotic resistance and protection of high-risk populations. The GMI is comprised of a multidisciplinary group of scientists and clinicians representing institutions from several continents. Areas covered: Given that the incidence and prevalence of IMD continually varies both geographically and temporally, and surveillance systems differ worldwide, the true burden of IMD remains unknown. Genomic alterations may increase the epidemic potential of meningococcal strains. Vaccination and (to a lesser extent) antimicrobial prophylaxis are the mainstays of IMD prevention. Experiences from across the globe advocate the use of conjugate vaccines, with promising evidence growing for protein vaccines. Multivalent vaccines can broaden protection against IMD. Application of protection strategies to high-risk groups, including individuals with asplenia, complement deficiencies and human immunodeficiency virus, laboratory workers, persons receiving eculizumab, and men who have sex with men, as well as attendees at mass gatherings, may prevent outbreaks. There was, however, evidence that reduced susceptibility to antibiotics was increasing worldwide. Expert commentary: The current GMI global recommendations were reinforced, with several other global initiatives underway to support IMD protection and prevention. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

Цитирование

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • R. Acevedo
    Biologic Evaluation Department, Finlay Institute of Vaccines, Havana, Cuba
  • X. Bai
    Meningococcal Reference Unit, Public Health England, Manchester, United Kingdom
  • R. Borrow
    Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway
  • D. Caugant
    Department of Pediatrics, College of Medicine, University of the East–Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines
  • J. Carlos
    Faculty of Medicine, Department of Pediatric Infectious Diseases, Hacettepe University, Ankara, Turkey
  • M. Ceyhan
    Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
  • H. Christensen
    Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada
  • Y. Climent
    Department of Paediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey
  • W. De
    Center for Research on Infectious Diseases, Instituto Nacional de Salud Pública, Cuernavaca, Mexico
  • E. Dinleyici
    Infectious Diseases Control, Ministry of Health, Riyadh, Saudi Arabia
  • G. Echaniz-Aviles
    Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan
  • A. Hakawi
    Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom
  • H. Kamiya
    Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, Johannesburg, South Africa
  • A. Karachaliou
    Central Research Institute of Epidemiology, Moscow, Russian Federation
  • J. Lucidarme
    Department of Pediatrics, FCM Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil
  • S. Meiring
    National Institute for Communicable Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, China
  • K. Mironov
    Meningitis Research Foundation, Bristol, United Kingdom
  • M. Sáfadi
    Department of Epidemiology and Prevention of Infectious Diseases, WHO Collaborating Centre for Travellers’ Health, University of Zurich, Zurich, Switzerland
  • Z. Shao
    Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden
  • V. Smith
    Institut Pasteur, National Reference Centre for Meningococci, Paris, France
  • R. Steffen
    National Centre of Microbiology, Institute of Health Carlos III, Madrid, Spain
  • B. Stenmark
  • M. Taha
  • C. Trotter
  • J. Vázquez
  • B. Zhu
Название журнала
  • Expert Review of Vaccines
Том
  • 18
Выпуск
  • 1
Страницы
  • 15-30
Ключевые слова
  • Meningococcus vaccine; antiinfective agent; Meningococcus vaccine; antibiotic resistance; bacterial meningitis; conjugate; disease surveillance; epidemic meningitis; genomics; high risk population; human; incidence; medical research; meningococcosis; Neisseria meningitidis; nonhuman; prevention and control; preventive health service; priority journal; Review; serotype; vaccination; virus strain; antibiotic resistance; epidemic; global health; meningococcosis; microbiology; risk factor; Anti-Bacterial Agents; Disease Outbreaks; Drug Resistance, Bacterial; Global Health; Humans; Meningococcal Infections; Meningococcal Vaccines; Risk Factors; Vaccination
Издатель
  • Taylor and Francis Ltd
Тип документа
  • Review
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus
COVID-19.рф: Информация против пандемии

Адрес: 115114, Москва, ул. Летниковская, д. 4, стр.5, офис 2.4
тел.\факс: +7(499)754-99-94, доб. 502
e-mail: covid19@neicon.ru

Проект реализуется с использованием гранта Президента Российской Федерации на развитие гражданского общества, предоставленного Фондом президентских грантов.

Содержимое сайта, если не указано иное, опубликовано в соответствии с лицензией Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная (CC BY 4.0). Права на материалы, переданные партнерами проекта, принадлежат их правообладателям.

© 2025 NEICON